Mesenteric Venous ThrombosisSymptoms, Doctors, Treatments, Advances & More
Learn About Mesenteric Venous Thrombosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Office
Samuel Goldhaber is a Cardiologist practicing medicine in Boston, Massachusetts. Dr. Goldhaber is rated as an Elite provider by MediFind in the treatment of Mesenteric Venous Thrombosis. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Pulmonary Embolism, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Embolectomy, and Thrombectomy.
Massachusetts General Hospital
Farouc Jaffer is a Cardiologist practicing medicine in Boston, Massachusetts. Dr. Jaffer is rated as an Elite provider by MediFind in the treatment of Mesenteric Venous Thrombosis. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Mesenteric Venous Thrombosis, Deep Vein Thrombosis, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery.
Office
Behnood Bikdeli is a Cardiologist practicing medicine in Boston, Massachusetts. He has been practicing medicine for over 18 years. Dr. Bikdeli is rated as an Elite provider by MediFind in the treatment of Mesenteric Venous Thrombosis. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism (VTE), Thrombectomy, and Percutaneous Coronary Intervention (PCI).
Summary: This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved...
Summary: Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associa...